Abbott unit secures injunction against Edwards
An English High Court judge has issued an injunction against Edwards Lifesciences, handing a victory to Abbott Laboratories subsidiary Evalve.
Uni of South Florida researchers accuse Hologic of patent infringement
The University of South Florida Research Foundation has accused medical technology company Hologic of patent infringement, related to diagnosis methods for digital mammography.
Phenytoin judgment will help clarify unfair pricing tests, says UK’s CMA
The UK Competition and Markets Authority has welcomed a Court of Appeal ruling allowing it to press ahead with cases against Pfizer and Flynn Pharma over the unfair pricing of an epilepsy treatment.
Texas uni wants Supreme Court to settle state sovereignty rules
The University of Texas has asked the Supreme Court to rule that state-owned institutions should escape the normal rules determining the appropriate venue for filing patent lawsuits.
No coronavirus-related drug shortages yet, says EMA
The European Medicines Agency has said that no drug shortages or supply disruptions due to the coronavirus outbreak have been reported, but that a steering group has convened to address the epidemic’s impact on the supply of medicines in the EU.
FDA, FTC send message to biologics makers at competition workshop
US drug and antitrust regulators have signalled their intent to crack down on anti-competitive behaviour in the biologics and biosimilar industries, in an effort to bring down prices.
Retirees interest group supports California’s pay-for-delay ban
The AARP has urged the US Court of Appeals for the Ninth Circuit to uphold a newly-formed California law prohibiting the majority of pay-for-delay pharmaceutical settlements.
Par avoids pay-for-delay suit after court accepts payment was ‘fair’
A Virginia judge has approved Par Pharmaceutical’s settlement with a group of direct purchasers, allowing the pharmaceutical company to escape a pay-for-delay lawsuit.
Europol notes ‘worrying trend’ in fake medicines
EU authorities seized €7.9 million worth of counterfeit medicines—including fake cancer drugs, antivirals, and erectile dysfunction medicines—as part of an operation carried out last year.
Gilead to face HIV antitrust claims
Drugmakers including Gilead Sciences must face antitrust claims related to HIV drugs, after the US District Court for the District of Florida on Monday, March 3 refused to fully throw out a class-action suit implicating the company.
